Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Emerging from Repeated Price Cuts, Opdivo’s Japan Sales Could Top 100 Billion Yen in FY2020
October 30, 2020
-
REGULATORY Japan to Receive 50 Million Doses of Moderna COVID-19 Vaccines via Takeda
October 29, 2020
-
BUSINESS GSK Might Adjust Shipments for Cervarix as Surge in Demand Expected
October 29, 2020
-
BUSINESS Copay Rose for Some Patients as Leuplin Issue Triggered Shortage of 6-Month Depot: HCPs
October 28, 2020
-
BUSINESS Pharma’s Half-Year Earnings Season in Full Swing from This Week
October 27, 2020
-
BUSINESS Ono Says Honjo’s 22.6 billion Yen Claim Groundless, No Agreement Reached on 40% Opdivo Fee Proposal
October 27, 2020
-
REGULATORY PM Suga Vows to Work towards Annual Price Revisions: Diet Policy Speech
October 27, 2020
-
REGULATORY 1st Working Group Meeting for Prioritization of “Stable Supply Medicines” Set for Early November
October 26, 2020
-
BUSINESS Novartis Looks to Solidify Presence in Multiple Sclerosis Arena with Mayzent, then Ofatumumab
October 23, 2020
-
BUSINESS GSK Sets Up Oncology Biz Unit in Japan; Multiple Late-Stage Assets in Pipeline
October 22, 2020
-
REGULATORY PMDA Sees Studies on Preventive Effect as a “Must” for Coronavirus Vaccines: Official
October 21, 2020
-
BUSINESS Pfizer, BioNTech Begin Japan PI/II Study for COVID-19 Vaccine
October 21, 2020
-
BUSINESS LEO Pharma’s Atopic Dermatitis Program Lags as PMDA Requests Japanese Data, but Growth Goal Intact
October 20, 2020
-
REGULATORY Japan Cannot Boast of Its Development Status of COVID-19 Vaccines/Drugs: LDP Health Committee Chair
October 20, 2020
-
REGULATORY 3 Mega Pharma-Drugs Now Approved in Japan with Continuous Manufacturing, Japan Players Could Follow Suit Soon: PMDA Specialist
October 19, 2020
-
BUSINESS Fujifilm Eyes Avigan Use in Mild and Severe COVID-19 Cases: Exec
October 19, 2020
-
BUSINESS (Update) Avigan Filed for COVID-19 in Japan: Fujifilm
October 16, 2020
-
BUSINESS Chugai, Roche Discussing Japan Development of Regeneron's COVID-19 Antibody Cocktail
October 16, 2020
-
BUSINESS Avigan Filed for COVID-19 in Japan: Fujifilm
October 16, 2020
-
BUSINESS Japan Sees Improved LHRH Agonist Supply as Leuprorelin Output Rises; Shipment Curbs for Substitutes Lifted
October 15, 2020
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…